181 related articles for article (PubMed ID: 12709044)
1. Pharmacokinetics of factor VIII and factor IX.
Morfini M
Haemophilia; 2003 May; 9 Suppl 1():94-9; discussion 100. PubMed ID: 12709044
[TBL] [Abstract][Full Text] [Related]
2. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
3. Individualized PK-based prophylaxis in severe haemophilia.
Dargaud Y; Delavenne X; Hart DP; Meunier S; Mismetti P
Haemophilia; 2018 Mar; 24 Suppl 2():3-17. PubMed ID: 29543364
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
Björkman S
Haemophilia; 2003 May; 9 Suppl 1():101-8; discussion 109-10. PubMed ID: 12709045
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetic studies in haemophilia.
Morfini M
Haemophilia; 2002 Mar; 8 Suppl 2():30-3. PubMed ID: 11966850
[TBL] [Abstract][Full Text] [Related]
6. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
7. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards.
Morfini M; Cinotti S; Bellatreccia A; Paladino E; Gringeri A; Mannucci PM;
J Thromb Haemost; 2003 Nov; 1(11):2283-9. PubMed ID: 14629459
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study.
Morfini M; Marchesini E; Paladino E; Santoro C; Zanon E; Iorio A
Haemophilia; 2015 Mar; 21(2):204-209. PubMed ID: 25274155
[TBL] [Abstract][Full Text] [Related]
9. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
Collins PW; Fischer K; Morfini M; Blanchette VS; Björkman S;
Haemophilia; 2011 Jan; 17(1):2-10. PubMed ID: 20731726
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project.
Hajducek DM; Chelle P; Hermans C; Iorio A; McEneny-King A; Yu J; Edginton A
Haemophilia; 2020 May; 26(3):384-400. PubMed ID: 32281726
[TBL] [Abstract][Full Text] [Related]
11. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis.
Morfini M; Lee M; Messori A
Thromb Haemost; 1991 Sep; 66(3):384-6. PubMed ID: 1746011
[No Abstract] [Full Text] [Related]
12. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
13. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.
Kessler CM; Gill JC; White GC; Shapiro A; Arkin S; Roth DA; Meng X; Lusher JM
Haemophilia; 2005 Mar; 11(2):84-91. PubMed ID: 15810908
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
Morfini M; Farrugia A
Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
[No Abstract] [Full Text] [Related]
15. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
Johnston A
Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
[TBL] [Abstract][Full Text] [Related]
16. Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.
Zwagemaker AF; Kloosterman FR; Gouw SC; Boyce S; Brons P; Cnossen MH; Collins PW; Eikenboom J; Hay C; Hengeveld RCC; Jackson S; Klopper-Tol CAM; Kruip MJHA; Gorkom BL; Male C; Nieuwenhuizen L; Shapiro S; Fijnvandraat K; Coppens M;
J Thromb Haemost; 2023 Apr; 21(4):850-861. PubMed ID: 36696222
[TBL] [Abstract][Full Text] [Related]
17. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
19. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
[TBL] [Abstract][Full Text] [Related]
20. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia.
Larsen MS; Juul RV; Groth AV; Simonsson USH; Kristensen AT; Knudsen T; Agersø H; Kreilgaard M
Eur J Pharm Sci; 2018 Mar; 115():196-203. PubMed ID: 29369801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
